The Pharma & Biotech team at Citigate Dewe Rogerson, the leading international consultancy specialising in financial and corporate communications, is pleased to provide an update of team and client activities during what has been a very busy final quarter of 2009.

The end of 2009 saw a sharp upswing in financing activity in Europe, with Citigate clients at the forefront. The nearly €100 million IPO on Euronext Brussels for GI company Movetis was the first significant IPO in the European life sciences sector since early 2008. The Citigate team also played an important role in supporting the €100 million placing and offering for NicOx and the €42 million follow-on offering for ThromboGenics, as well as in several smaller fundraisings for private biotech companies.

Citigate also worked on behalf of Novexel in relation to its €505 million acquisition by AstraZeneca and for Clavis Pharma on its US $380 million agreement with Clovis Oncology for CP-4126, a novel cancer treatment.

Outside financial PR, the team was involved in an investor summit for the UK Government Department for Business Innovation & Skills to raise awareness of its UK Innovation Investment Fund (UKIIF). The summit was opened by Secretary of State Lord Mandelson and included speakers from within venture capital, fund management and innovative UK businesses. The summit was followed by Science and Innovation Minister Lord Drayson's announcement of the appointment of Hermes Private Equity and the European Investment Fund (EIF) as the Fund-of-Funds managers for the UKIIF.

Working with our sister agency, Huntsworth Health, the team has also been coordinating an international publicity campaign (USA, UK and Germany) designed to drive patient recruitment into Algeta's global Phase III clinical trial with Alpharadin for treating bone metastases in prostate cancer patients. The team's work on the UK launch of Genzyme's Mozobil® (plerixafor) was also recognised as the client's communication campaign of the year.

New Clients
	Movetis is a European specialty pharmaceutical company focused on the discovery, development and commercialisation of proprietary, innovative and differentiated drugs for the treatment of diseases in the GI area. Citigate was appointed to provide strategic communications advice and execution in relation to the Company's IPO on Euronext Brussels.
	Immatics is a clinical stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics' lead product, IMA901, has completed a Phase II trial in renal cell carcinoma and its pipeline also includes candidates for colorectal cancer and glioblastoma. immatics' technology platform rapidly generates highly defined therapeutic cancer vaccines which are based on multiple tumour-associated peptides (TUMAPs), which specifically stimulate the immune system against cancer cells.
Portfolio Company News (click links for further details) Financial News arGEN-X concludes €12.5 million Series A financing arGEN-x is awarded €1.3 million grant for the development of its SIMPLE antibody™ platform Swiss diagnostics firm Biocartis raises €10 million in Series A round Clavis Pharma receives NOK20 million loan from Innovation Norway to support the Phase III development of elacytarabine in acute myeloid leukaemia Cambridge, UK-based Crescendo Biologics raises £4.5 million in seed funding to advance the development of its fragment antibody technology platforms Movetis raises €97.75 million in initial public offering on Euronext Brussels NicOx raises €100 million via two-step capital increase ThromboGenics raises €42 million in private placement Corporate and Business Development arGEN-X opens new R&D facility in Flanders (Belgium) to become center of excellence for discovery and development of therapeutic antibodies UK Government on course to create Europe's largest technology venture capital fund Clavis Pharma signs US $380 million agreement for development and commercialization of its anti-cancer agent CP-4126 with Clovis Oncology Heptares Therapeutics signed US $200 million agreement with Novartis Option Fund to apply its StaR™ technology and generate novel drug leads against a designated GPCR Target Novexel to be acquired for US $505 million by AstraZeneca ThromboGenics and BioInvent win 'Licensing Deal of the Year' at the Scrip Awards 2009 for strategic partnership with Roche for anti-cancer antibody TB-403 Product Development Amarin enrols first patients into two Phase 3 clinical trials assessing AMR101 for the treatment of cardiovascular disease Positive Phase II clinical data for Clavis Pharma's elacytarabine presented at ASH annual meeting Clavis Pharma receives US orphan drug designation for CP-4126 to treat pancreatic cancer Chi-Med collaborates with University of Cambridge to study the angiogenesis effect of various substances derived from chinese medicinal plants All primary and secondary endpoints achieved in Chi-Med's Phase IIb trial with HMPL-004 in ulcerative colitis Movetis obtains EU authorisation for the commercialisation of Resolor® (prucalopride) NicOx submits naproxcinod MAA to the EMEA as a new treatment to relieve the signs and symptoms of osteoarthritis FDA accepts NicOx' NDA filing for naproxcinod ThromboGenics starts Phase II trial of microplasmin for the treatment of age-related macular degeneration ThromboGenics completes patient enrolment of second Phase III trial of Microplasmin for the non-surgical treatment of eye disease Vantia Therapeutics' VA111913 enters Phase II proof-of-concept trials for dysmenorrhoea People and Appointments Amarin appoints industry veteran Joseph Zakrzewski as Executive Chairman and John F. Thero as Chief Financial Officer Crescendo Biologics appoints Clive Dix as Chairman Clavis Pharma appoints Olav Hellebo as Chief Executive Officer Mozobil is a registered trademark of Genzyme Corporation.